公开(公告)号：EP3686275A1

公开(公告)日：2020-07-29

申请号：EP18857205.1

申请日：2018-09-18

申请人： Edigene Inc.

发明人： YUAN, Pengfei ,  WANG, Fei ,  YU, Lingling ,  DONG, Xi

IPC分类号： C12N5/10

摘要： Provided are a universal T cell and preparation method thereof. The universal T cells comprise CAR-T and TCR-T cells, and are obtained by knocking out TCR and/or HLA and/or PD-1 proteins of T cells by a CRISPR/Cas9 genome editing technology, wherein the universal CAR-T continues to kill target cells in vivo and in vitro.

公开(公告)号：EP4026910A1

公开(公告)日：2022-07-13

申请号：EP20861118.6

申请日：2020-09-04

申请人： Edigene Inc.

发明人： YUAN, Pengfei ,  FANG, Riguo ,  JIN, Ming ,  ZHANG, Yongjian

IPC分类号： C12N15/90 ,  C12N5/10 ,  A61K35/28 ,  A61P35/00 ,  A61K38/17 ,  A61K48/00

摘要： Disclosed is a method for determining the suitability of a cell therapy for an individual. By means of using a bioinformatic method and an experimental analysis method for an unbiased potential off-target site, a potential off-target site of a genetically modified cell from an individual is predicted before administering a cell therapy to an individual, and the potential off-target site is monitored after administering, to the individual, the genetically modified cell from the individual to determine whether gene editing occurs at the potential off-target site and to evaluate the suitability of the therapy on the basis of the occurrence of a gene editing event.

公开(公告)号：EP3956449A1

公开(公告)日：2022-02-23

申请号：EP20792124.8

申请日：2020-04-15

申请人： Edigene Inc. ,  Peking University

发明人： YUAN, Pengfei ,  ZHAO, Yanxia ,  LIU, Nengyin ,  YI, Zexuan ,  TANG, Gangbin ,  WEI, Wensheng ,  QU, Liang ,  YI, Zongyi ,  ZHU, Shiyou ,  WANG, Chunhui ,  CAO, Zhongzheng ,  ZHOU, Zhuo

IPC分类号： C12N15/113 ,  C12N15/11 ,  C12N15/10 ,  A61K31/712

公开(公告)号：EP3702459A1

公开(公告)日：2020-09-02

申请号：EP18870546.1

申请日：2018-10-26

申请人： Edigene Inc.

发明人： YUAN, Pengfei ,  FANG, Riguo ,  YU, Lingling ,  XIA, Penghui ,  WANG, Jia ,  LIANG, Fucai

IPC分类号： C12N15/113 ,  C12N5/22 ,  C12N9/22 ,  A61K35/18 ,  A61P7/06

摘要： Provided is a method for genetically editing an enhancer locus of hematopoietic stem cell BCL11A, comprising: disrupting the CTTCCT region of a BCL11A genome by gene editing technology. The genetically edited hematopoietic stem cells have normal cell functions and can significantly increase the expression of fetal hemoglobin, thereby being used for the treatment of β thalassemia and sickle cell anemia.

公开(公告)号：EP3864152A1

公开(公告)日：2021-08-18

申请号：EP19870299.5

申请日：2019-10-12

申请人： Peking University ,  Edigene Inc.

发明人： WEI, Wensheng ,  QU, Liang ,  YI, Zongyi ,  ZHU, Shiyou ,  WANG, Chunhui ,  CAO, Zhongzheng ,  ZHOU, Zhuo ,  YUAN, Pengfei

IPC分类号： C12N15/113 ,  C12N15/11 ,  C12N15/10 ,  A61K31/712

公开(公告)号：EP3702458A1

公开(公告)日：2020-09-02

申请号：EP18870256.7

申请日：2018-10-26

申请人： Edigene Inc.

发明人： YUAN, Pengfei ,  FANG, Riguo ,  YU, Lingling ,  XIA, Penghui ,  WANG, Jia ,  LIANG, Fucai

IPC分类号： C12N15/113 ,  C12N5/22 ,  C12N9/22 ,  A61K35/18 ,  A61P7/06

摘要： Provided is a method for gene editing of an enhancer site of the BCL11A in hematopoietic stem cells. The genetically modified hematopoietic stem cells have the functions of normal cells, and can significantly increase the expression of fetal hemoglobin so as to be used in the treatment of β thalassemia and sickle cell anemia.